NCT04156698View on ClinicalTrials.gov

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 21, 2020

Primary Completion Date

April 16, 2023

Study Completion Date

January 16, 2026

Conditions
Hypopharyngeal CarcinomaImmunotherapyChemotherapy
Interventions
DRUG

Docetaxel

Docetaxel is a chemotherapy drug.

DRUG

Cisplatin

Cisplatin is a chemotherapy drug.

DRUG

Capecitabine

Capecitabine is a chemotherapy drug.

DRUG

Camrelizumab

Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.

Trial Locations (1)

200031

Eye & ENT Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Eye & ENT Hospital of Fudan University

OTHER